X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ALEMBIC PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ALEMBIC PHARMA SANOFI INDIA/
ALEMBIC PHARMA
 
P/E (TTM) x 35.7 15.1 237.1% View Chart
P/BV x 6.3 3.5 180.4% View Chart
Dividend Yield % 1.4 1.1 126.7%  

Financials

 SANOFI INDIA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
ALEMBIC PHARMA
Mar-19
SANOFI INDIA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs6,840664 1,030.1%   
Low Rs4,630412 1,122.7%   
Sales per share (Unadj.) Rs1,203.1208.7 576.4%  
Earnings per share (Unadj.) Rs165.331.0 533.1%  
Cash flow per share (Unadj.) Rs209.937.1 565.5%  
Dividends per share (Unadj.) Rs84.005.50 1,527.3%  
Dividend yield (eoy) %1.51.0 143.3%  
Book value per share (Unadj.) Rs963.6144.2 668.2%  
Shares outstanding (eoy) m23.03188.52 12.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.82.6 184.9%   
Avg P/E ratio x34.717.4 199.9%  
P/CF ratio (eoy) x27.314.5 188.4%  
Price / Book Value ratio x6.03.7 159.5%  
Dividend payout %50.817.7 286.5%   
Avg Mkt Cap Rs m132,078101,461 130.2%   
No. of employees `0003.3NA-   
Total wages/salary Rs m4,0687,467 54.5%   
Avg. sales/employee Rs Th8,393.8NM-  
Avg. wages/employee Rs Th1,232.4NM-  
Avg. net profit/employee Rs Th1,153.0NM-  
INCOME DATA
Net Sales Rs m27,70839,347 70.4%  
Other income Rs m89794 956.3%   
Total revenues Rs m28,60539,441 72.5%   
Gross profit Rs m6,2358,736 71.4%  
Depreciation Rs m1,0271,152 89.1%   
Interest Rs m7184 3.8%   
Profit before tax Rs m6,0987,493 81.4%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2921,568 146.2%   
Profit after tax Rs m3,8065,844 65.1%  
Gross profit margin %22.522.2 101.4%  
Effective tax rate %37.620.9 179.7%   
Net profit margin %13.714.9 92.5%  
BALANCE SHEET DATA
Current assets Rs m15,92219,577 81.3%   
Current liabilities Rs m6,23514,896 41.9%   
Net working cap to sales %35.011.9 293.9%  
Current ratio x2.61.3 194.3%  
Inventory Days Days6490 70.9%  
Debtors Days Days2145 46.0%  
Net fixed assets Rs m7,53927,097 27.8%   
Share capital Rs m230377 61.0%   
"Free" reserves Rs m21,96226,811 81.9%   
Net worth Rs m22,19227,188 81.6%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m29,83947,778 62.5%  
Interest coverage x872.141.7 2,091.4%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.90.8 112.8%   
Return on assets %12.812.6 101.3%  
Return on equity %17.221.5 79.8%  
Return on capital %27.523.6 116.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58719,453 39.0%   
Fx outflow Rs m7,1456,065 117.8%   
Net fx Rs m44213,388 3.3%   
CASH FLOW
From Operations Rs m3,7398,120 46.0%  
From Investments Rs m-731-7,556 9.7%  
From Financial Activity Rs m-1,972590 -334.0%  
Net Cashflow Rs m1,0361,153 89.8%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 2.9 496.6%  
FIIs % 14.6 9.1 160.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 13.9 75.5%  
Shareholders   15,184 49,328 30.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 23, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS